ArticleAsian Pacific journal of cancer prevention : APJCP2025
Quantification of Circulating HPV DNA as a Biomarker for Cervical pre-cancer and cancer: A Pilot Study.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Minimal residual disease in cervical cancer: biological persistence, ctHPV DNA-guided surveillance, and recurrence-directed intervention.Frontiers in oncology · 2026Review
- Association and interaction network analysis of immune cell subgroups in cervical cancer microenvironment based on Mendelian randomization.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor cells release fragments of their DNA into the bloodstream, called cell-free tumor DNA (ctDNA) or liquid biopsy. In this study, we investigate whether human papillomavirus cell-free tumor DNA (ctHPV DNA) can be detected in patients with cervical cancer or premalignant lesions before and after treatment. We are also investigating whether ctHPV DNA levels correlate with patient or tumor characteristics and outcomes.
methodsA total of 67 cases were included, including 42 with locally advanced cervical cancer (LACC) and 11 with early-stage cervical cancer (ESCC), as well as 14 with premalignant lesions. Pre- and post-treatment plasma samples were tested for ctHPV DNA levels using digital droplet PCR.
resultsThe pretreatment ctHPV DNA was detected in 21.42%(n=09/42) cases with LACC and post treatment ctHPV DNA was detected in 16.66% (07/42) LACC cases. While circulating ctHPV DNA was not detected in ESCC and premalignant lesion cases. Higher levels of ctHPV DNA were correlated to the higher FIGO2018 stage.
conclusionctHPV DNA is a promising biomarker in locally advanced cervical cancer and should be further investigated for clinical use. In ESCC patients, the detection rate of ctHPV DNA is not sufficient for clinical benefit even using ddPCR, the most sensitive technologies available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.